Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche BankProactive Investors • 05/20/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyThe Motley Fool • 05/19/26
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi saysProactive Investors • 05/18/26
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wastingWSJ • 05/17/26
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026GlobeNewsWire • 05/13/26
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated personsGlobeNewsWire • 05/12/26
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weightCNBC • 05/12/26
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on ObesityGlobeNewsWire • 05/12/26
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on ObesityGlobeNewsWire • 05/12/26
Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelinesProactive Investors • 05/11/26